5 / 20
Page 25
Journal of Medical Physics and Applied Sciences
ISSN: 2574-285X
I n t e r n a t i o n a l C o n f e r e n c e o n
Nuclear Medicine &
Radiation Therapy
Nuclear Medicine & Radiation Therapy 2018
O c t o b e r 0 1 - 0 2 , 2 0 1 8
S t o c k h o l m , S w e d e n
Biography
Pal Mikecz has received his University Doctoral Degree in 1988
based on the work of Production Methods of Medically Im-
portant Radioisotopes which was conducted in Joint Nuclear
Research Institute in Dubna. Since then, he had participated in
establishment and running a few PET radiochemistry laborato-
ries in Hungary, Scotland, Poland and Germany. He has recently
retired from the University of Debrecen. He is Senior Advisor for
the Radiochemistry Laboratory of the newest Hungarian PET
centre at the Kaposi Mór Teaching Hospital in Kaposvár. He had
participated in several IAEA mission as an Expert in the field of
PET Radiochemistry. He has published more than 50 papers in
reputed journals with 500+ citations and has been serving as
Reviewer of many articles.
mcpalmc@gmail.comProduction of radiopharmaceuticals suitable aiding
radiotherapy planning
Pal Mikecz
Kaposi Mor Teaching Hospital-Medicopus Non-profit Ltd, Hungary
Pal Mikecz, J. med phys & appl sci 2018, Volume: 3
DOI: 10.21767/2574-285X-C1-002
P
ositron emission tomography (PET) could significantly improve the radiation
therapy planning by increasing the targeting accuracy and therapeutic efficacy
of the delivered radiation. Since this method gives information of the biochemistry
of tissues, it should be a necessary supplement to the anatomical imaging
methods such as CTor MRI. Themain advantage is its ability in imagemetabolism,
apoptosis, proliferation, cellular transporters, cell receptors, oxygen availability,
gene expression and cell kinetics, non-invasively in living subjects at multiple time
points. Besides the 2-[fluorine-18] fluoro-2-deoxy-D-glucose (FDG), the most often
applied radiopharmaceutical, there are several other well established but much
less used tracers. The use of other tracers is often hindered by price and the lack
of availability of these tracers. The second most frequently used tracer family
is the fluorine-18 or carbon-11 labelled amino acids like [11C] methionine, [
18
F]
Fluoro (methyl or ethyl) tyrosine or even [
18
F] FDOPA (fluorodopa). The carbon-11
and fluorine-18 labelled choline analogues could be useful in prostate tumour
metastases or in some cases in gliomas. Since hypoxic tumour cells are relatively
resistant to radiation and would be more likely to be controlled if a higher radiation
dose could be accurately targeted at regions of imaged hypoxia with [
18
F] FMISO
(fluoromisonidazole) or [
18
F] FAZA (Fluoroazomycin arabinoside ). The ideal
radionuclide for PET imaging is fluorine-18 due to its ideal nuclear properties.
Application of other nuclides is always call for compromise in image quality. The
acceptance of the radiopharmaceuticals by the end users, i.e., clinicians and the
patients is important, however, the approval by the national regulatory agency and
above all reimbursement for theparticular clinical indicationare critical factors that
determine the success of a scientifically useful molecular imaging agent. Recently
in Hungary there are four tracers that are available for human applications. Their
use for radiation therapy planning so far was not commenced.